Ph I Dasatinib + Erlotinib in Recurrent MG

Inclusion Criteria: * Diagnosis of recurrent/progressive WHO grade IV MG or WHO grade III MG. Pts with prior low-grade glioma are eligible if histologic assessment demonstrates transformation to WHO grade III / IV MG * \>18 yrs * Karnofsky Performance Status \>70 percent * Pts presenting in 1st, 2nd / 3rd relapse. Prior therapy must have included external beam XRT * Adequate bone marrow, liver \& renal function as assessed by following: * Hemoglobin\>9.0g/dl * ANC\>1,500/mm3 * Platelet count\>100,000/mm3 * Total bilirubin\<1.5 x ULN * ALT \& AST\<2.5 x ULN * INR\<1.5 or PT/PTT within normal limits. Pts receiving anti-coagulation treatment w low-molecular weight heparin allowed to participate, oral warfarin is not permitted * Creatinine\<1.5 x ULN * Serum Na, K+, Mg2+, Phosphate \& Ca2+ \>LLN * Interval\<2 wks between prior surgical resection \& initiation of study regimen * Interval \<12 weeks from completion of standard, daily XRT, unless one of following occurs: new area of enhancement on MRI imaging that is outside XRT field; biopsy proven recurrent tumor; / radiographic evidence of progressive tumor on 2 consecutive scans \>4 wks apart. * Interval \<4weeks from prior chemotherapy unless there is unequivocal evidence of tumor progression \& pt has recovered from all anticipated toxicities from prior therapy * Interval \<4weeks from prior investigational agent unless there is unequivocal evidence of tumor progression \& pt has recovered from all anticipated toxicities from prior therapy * Signed written informed consent including HIPAA according to institutional guidelines. Signed informed consent must be obtained prior to any study specific procedures * If sexually active, pts will take contraceptive measures for duration of treatments \& for 4 weeks following discontinuation of dasatinib \& Erlotinib. * Women of childbearing potential must have negative serum or urine pregnancy test within 72 hrs prior to start of study drug administration Exclusion Criteria: * No prior dasatinib / oral EGFR-inhibitor therapy * Pregnancy/breast feeding * History of significant concurrent illness -\>3 prior episodes of progressive disease * Significant cardiac disease * Excessive risk of bleeding as defined by stroke \<6 months, history of CNS / intraocular bleed,/ septic endocarditis. * Concurrent severe and/or uncontrolled medical disease that could compromise participation in study including any of following: pleural / pericardial effusion of any grade; uncontrolled diabetes; uncontrolled hypertension; active clinically serious infection \>CTCAEv3 Gr2 requiring active intervention; history of clinically-significant bleeding diathesis or coagulopathy including platelet function disorder or acquired bleeding disorder within 1yr; impairment of GI function /GI disease that may significantly alter absorption of study regimen; ongoing or recent significant gastrointestinal bleeding * Thrombolic or embolic events such as cerebrovascular accident including transient ischemic attacks \<6 months * Any hemorrhage/bleeding event \>CTCAEv3AE Gr3 within 4wks of 1st dose of study drug * Serious non-healing wound, ulcer, /bone fracture * Major surgery, open biopsy /significant traumatic injury \<4 weeks of 1st study drug * Known HIV infection/chronic Hepatitis B/C * Pt is \<3yrs free of another primary malignancy except: if other primary malignancy is either not currently clinically significant/does not require active intervention. Existence of any other malignant disease is not allowed. * Pts unwilling to/unable to comply with protocol including ability to swallow whole pills/presence of any malabsorption syndrome * Concurrent administration of warfarin, rifampin/St. John's Wort * Subjects w hypokalemia/hypomagnesemia if it cannot be corrected * Prisoners/subjects who are compulsorily detained for treatment of either psychiatric/physical illness